- Cohort 3 analysis from the BREAKWATER study shows objective response rate of 64% with BRAFTOVI plus cetuximab and FOLFIRI compared to 39% with standard-of-care treatment FOLFIRI with or without bevacizumab
- The BREAKWATER study demonstrates…
4Q 2025 Earnings Call
ExxonMobil is hosting its fourth-quarter 2025 earnings call from 8:30 a.m. to approximately 9:30 a.m. central time on Friday, January 30th. Presenters include…




